Anxiety · children with cancer
1 finding from 1 review
Depression · children with cancer
1 finding from 1 review
Incidence of HUS · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (3.0 mg/kg) changes incidence of HUS compared with placebo (very low certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) may leads to lower adverse events ‐ serious compared with placebo (low certainty).
1 finding from 1 review
Need for acute dialysis · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurological complications · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (3.0 mg/kg) changes neurological complications compared with placebo (very low certainty).
1 finding from 1 review
Death (any cause) · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (3.0 mg/kg) changes death (any cause) compared with placebo (very low certainty).
1 finding from 1 review
Incidence of HUS · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (1.0 mg/kg) changes incidence of HUS compared with placebo (very low certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (1.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
1 finding from 1 review
Need for acute dialysis · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurological complications · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (1.0 mg/kg) changes neurological complications compared with placebo (very low certainty).
1 finding from 1 review
Death (any cause) · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (1.0 mg/kg) changes death (any cause) compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Change in anxiety · various, including general population, pregnant people, psychiatric populations (ADHD, alcohol use disorder, anxiety disorder, depression,…
1 finding from 1 review
Intervention not reported
Change in depression · various, including general population, pregnant people, psychiatric populations (ADHD, alcohol use disorder, anxiety disorder, depression,…
1 finding from 1 review
Intervention not reported
Mixed anxiety and depression · various, including general population, pregnant people, psychiatric populations (ADHD, alcohol use disorder, anxiety disorder, depression,…
1 finding from 1 review
All‐cause mortality · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether portosystemic shunts changes all‐cause mortality compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Mortality due to rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether total shunt changes mortality due to rebleeding compared with endoscopic intervention (very low certainty).
1 finding from 1 review
Acute hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether total shunt changes acute hepatic encephalopathy compared with endoscopic intervention (very low certainty).
1 finding from 1 review